These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21282357)

  • 1. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
    Cen O; Longnecker R
    Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
    Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Pathways of p27
    Sora RP; Ikeda M; Longnecker R
    mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
    Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O
    Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
    Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
    Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
    Perez-Chacon G; de Los Rios C; Zapata JM
    Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
    Ikeda M; Hayes CK; Schaller SJ; Longnecker R
    Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
    Bieging KT; Amick AC; Longnecker R
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
    De Leo A; Arena G; Stecca C; Raciti M; Mattia E
    Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
    Fish K; Chen J; Longnecker R
    Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I; Jain V; Bhatia K
    Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
    Bultema R; Longnecker R; Swanson-Mungerson M
    Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas.
    Syrjänen S; Kallio P; Sainio P; Fuju C; Syrjänen K
    Scand J Dent Res; 1992 Jun; 100(3):176-80. PubMed ID: 1321486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?
    Allday MJ
    Semin Cancer Biol; 2009 Dec; 19(6):366-76. PubMed ID: 19635566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBV latent membrane protein 2A orchestrates p27
    Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
    Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epstein-Barr virus and Burkitt's lymphoma].
    Joab I
    Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.
    D'Souza B; Rowe M; Walls D
    J Virol; 2000 Jul; 74(14):6652-8. PubMed ID: 10864681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells.
    Rechsteiner MP; Berger C; Weber M; Sigrist JA; Nadal D; Bernasconi M
    J Gen Virol; 2007 May; 88(Pt 5):1454-1459. PubMed ID: 17412973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.